PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.00%
Revenue growth above 1.5x 3141.T's 3.82%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
3.45%
Gross profit growth under 50% of 3141.T's 8.87%. Michael Burry would be concerned about a severe competitive disadvantage.
-12.72%
Negative EBIT growth while 3141.T is at 19.47%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.49%
Negative operating income growth while 3141.T is at 57.72%. Joel Greenblatt would press for urgent turnaround measures.
44.66%
Net income growth comparable to 3141.T's 43.24%. Walter Schloss might see both following similar market or cost trajectories.
44.66%
EPS growth similar to 3141.T's 43.27%. Walter Schloss would assume both have parallel share structures and profit trends.
44.66%
Similar diluted EPS growth to 3141.T's 43.27%. Walter Schloss might see standard sector or cyclical influences on both firms.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.07%
10Y revenue/share CAGR under 50% of 3141.T's 86.84%. Michael Burry would suspect a lasting competitive disadvantage.
-13.38%
Negative 5Y CAGR while 3141.T stands at 57.32%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
32.50%
3Y revenue/share CAGR similar to 3141.T's 31.70%. Walter Schloss would assume both companies experience comparable short-term cycles.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
141.27%
Below 50% of 3141.T's 300.23%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
37.60%
Below 50% of 3141.T's 113.84%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
124.28%
3Y net income/share CAGR above 1.5x 3141.T's 39.22%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
132.72%
10Y equity/share CAGR at 50-75% of 3141.T's 177.44%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
27.89%
Below 50% of 3141.T's 114.35%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
71.06%
3Y equity/share CAGR above 1.5x 3141.T's 28.71%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-25.00%
Cut dividends over 10 years while 3141.T stands at 12264.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
2.27%
Below 50% of 3141.T's 220.00%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
-25.00%
Negative near-term dividend growth while 3141.T invests at 96.92%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-37.14%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
3.40%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
8.47%
Asset growth above 1.5x 3141.T's 2.73%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.41%
BV/share growth above 1.5x 3141.T's 3.79%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
25.46%
Debt growth far above 3141.T's 12.60%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-42.69%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.